Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease | Zendy

Wendy E. Boertien | Zendy; Esther Meijer | Zendy; Debbie Zittema | Zendy; Marjan A. van Dijk | Zendy; Ton J. Rabelink | Zendy; M.H. Breuning | Zendy; J. Struck | Zendy; Stephan J. L. Bakker | Zendy; Dorien J.M. Peters | Zendy; Paul E. de Jong | Zendy; Ron T. Gansevoort | Zendy

Open Access

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease

Author(s) -

Wendy E. Boertien,

Esther Meijer,

Debbie Zittema,

Marjan A. van Dijk,

Ton J. Rabelink,

M.H. Breuning,

J. Struck,

Stephan J. L. Bakker,

Dorien J.M. Peters,

Paul E. de Jong,

Ron T. Gansevoort

Publication year - 2012

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs070

Subject(s) - copeptin , medicine , vasopressin , surrogate endpoint , endocrinology , autosomal dominant polycystic kidney disease , renal function , kidney disease , polycystic kidney disease , kidney

Experimental studies have suggested that vasopressin plays a detrimental role in autosomal dominant polycystic kidney disease (ADPKD). It is, however, unknown whether endogenous vasopressin concentration is associated with kidney function decline in subjects with ADPKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research